首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL20 |
| Uniprot No | Q9NYY1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-176aa |
| 氨基酸序列 | LKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGNIDIRILRRTESLQDT KPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSLANSFLTIKKDLR LCHAHMTCHCGEEAMKKYSQILSHFEKLEPQAAVVKALGELDILLQWMEE TE |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-20重组蛋白的典型研究文献摘要概括：
1. **《IL-20 promotes cutaneous inflammation through induction of proinflammatory cytokines in keratinocytes》**
- **作者**: Wei CC et al.
- **摘要**: 研究通过重组IL-20蛋白体外刺激人角质形成细胞，发现其激活STAT3信号通路，上调IL-6、IL-8的表达，提示IL-20在银屑病等皮肤炎症中的作用机制。
2. **《Interleukin-20 regulates angiogenesis in rheumatoid arthritis》**
- **作者**: Hsu YH et al.
- **摘要**: 利用重组IL-20蛋白处理类风湿关节炎滑膜细胞，发现其通过VEGF依赖途径促进血管生成，表明IL-20可能在关节破坏和炎症进展中起关键作用。
3. **《IL-20 modulates tumor-associated angiogenesis in hepatocellular carcinoma》**
- **作者**: Chen W et al.
- **摘要**: 体外实验显示，重组IL-20蛋白通过激活内皮细胞ERK通路增强血管生成能力，提示IL-20可能成为肝癌抗血管治疗的潜在靶点。
4. **《IL-20 signaling in skeletal cells inhibits osteoblast differentiation》**
- **作者**: Sims NA et al.
- **摘要**: 研究发现重组IL-20蛋白通过抑制成骨细胞分化相关基因(如Runx2)，揭示了IL-20在骨质疏松等骨代谢疾病中的病理意义。
注：以上文献信息为示例性概括，实际研究中建议通过PubMed或Web of Science检索具体论文(可尝试关键词：IL-20 recombinant protein/function/therapeutic)。
Interleukin-20 (IL-20), a member of the IL-10 cytokine family, was discovered in the early 2000s and has since been recognized for its role in inflammatory and immune responses. Structurally, it shares homology with IL-10. IL-19. IL-22. and IL-24. functioning through two heterodimeric receptor complexes: IL-20R1/IL-20R2 and IL-22R1/IL-20R2. IL-20 is primarily produced by immune cells (e.g., monocytes, T cells) and epithelial cells, exerting effects on keratinocytes, endothelial cells, and fibroblasts. It regulates cell proliferation, differentiation, and angiogenesis, with notable involvement in skin disorders, rheumatoid arthritis, and cancer progression.
Recombinant IL-20 protein is engineered using expression systems like *E. coli* or mammalian cells (e.g., CHO), enabling large-scale production of bioactive forms for research and therapeutic exploration. Its applications span *in vitro* and *in vivo* studies to dissect signaling pathways, immune modulation, and tissue remodeling mechanisms. Preclinical studies highlight its dual role: while promoting wound healing and epithelial repair, IL-20 overexpression correlates with chronic inflammation in psoriasis and atherosclerosis. In oncology, IL-20’s angiogenic properties and crosstalk with tumor microenvironments are under investigation, though its pro- or anti-tumor effects remain context-dependent.
Therapeutic targeting of IL-20 pathways, including neutralizing antibodies or recombinant proteins, is being explored for inflammatory diseases. However, challenges persist in balancing its pleiotropic functions and minimizing off-target effects. Continued research aims to clarify its mechanistic nuances and unlock clinical potential.
×
